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Preterm birth is the leading cause of death worldwide in children under five years. Due to its complex 
multifactorial nature, prediction is a challenge. current research is aiming to develop accurate 
predictive models using patient history, ultrasound and biochemical markers. Volatile organic 
compound (Voc) analysis is an approach, which has good diagnostic potential to predict many 
disease states. Analysis of VOCs can reflect both the microbiome and host response to a condition. 
We aimed to ascertain if VOC analysis of vaginal swabs, taken throughout pregnancy, could predict 
which women go on to deliver preterm. our prospective observational cohort study demonstrates 
that VOC analysis of vaginal swabs, taken in the midtrimester, is a fair test (AUC 0.79) for preterm 
prediction, with a sensitivity of 0.66 (95%CI 0.56–0.75) and specificity 0.89 (95%CI 0.82–0.94). Using 
vaginal swabs taken closest to delivery, VOC analysis is a good test (AUC 0.84) for the prediction of 
preterm birth with a sensitivity of 0.73 (95%CI 0.64–0.81) and specificity of 0.90 (95%CI 0.82–0.95). 
Consequently, VOC analysis of vaginal swabs has potential to be used as a predictive tool. With further 
work it could be considered as an additional component in models for predicting preterm birth.
Globally, preterm birth is the leading cause of death in children under 5 years with 15 million babies being born 
before 37 weeks’ gestation each  year1. Spontaneous preterm birth is a syndrome, which can be precipitated by 
a variety of factors (or combination of these) including; infection, inflammation, vascular disease and uterine 
 overdistention2. The multifactorial complex nature of spontaneous preterm birth makes its prediction a chal-
lenge. A number of factors are needed to activate one or more of the common pathways required for myometrial 
contractions leading to the premature onset of labour, these include a maternal susceptibility, and an infective, 
inflammatory, ischaemic or mechanical (over distention)  insult3. Increasingly research is being carried out to 
try to improve the predictive value of various tests for preterm birth, including the development of prognostic 
models that account for both the maternal susceptibility and the insult, using patient history, ultrasound find-
ings and  biomarkers4–8. First, this aims to enable earlier interventions to facilitate targeted prevention strategies. 
Secondly to permit better prediction of those patients whom will deliver preterm, to assist in timely administra-
tion of treatments to optimise neonatal outcomes, whilst reducing their unnecessary administration as they are 
not without  ramifications9,10.
The association between bacterial vaginosis (BV) detected using laboratory techniques and preterm labour 
has been recognised for many  years11. Its presence, detected in early pregnancy is associated with an increased 
risk of preterm  labour11. Despite this, treatment of BV with antibiotics has not been demonstrated to prevent 
preterm birth as demonstrated by a recent randomised controlled trial (RCT) and a preceding systematic review 
and meta-analysis12,13. However, this trial focused on the low risk population for spontaneous preterm birth,12 
and the meta-analysis had substantial heterogeneity  (I2 = 48%)13, therefore treatment of the high risk population 
for BV with antibiotics to reduce the risk of preterm birth could warrant further investigation due to numerous 
factors contributing to the onset of preterm labour in a susceptible individual.
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A characteristic of bacterial vaginosis is a lack of lactobacilli and an increase in other  organisms11. More 
recently molecular-based technologies have allowed for the description of the bacterial component of the vaginal 
microbiome. These molecular-based techniques have found that a vaginal microbiome with reduced Lactobacil-
lus spp. abundance and increased bacterial diversity is associated with preterm  delivery14–18 and that this can be 
detected prior to the onset of  symptoms14.
The mutualistic association between the vagina and the microbiota is a fine balance under the influence of 
many factors, including sex steroid  hormones19–23, sexual  activity24,25 and hygiene  practices25,26.
Volatile organic compound (VOC) analysis is a technique to monitor microbiota and its metabolic activ-
ity, providing insight into the interactions between microbiota and their host. It provides a non-invasive and 
potentially rapid means to monitor the microbiota and host response. In recent years, VOCs have been demon-
strated as a non-invasive diagnostic biomarkers for several diseases including inflammatory bowel  disease27–29, 
 cancers30,31,  sepsis32 and  diabetes33. With recent developments in VOC detection and analysis technology it now 
has the potential to be realistically translated into clinical practice.
In some cases preterm labour is thought to be the result of both vaginal flora and host response to this  flora34. 
Thus, for the prediction of preterm labour, a test that both detects differences in the vaginal flora and the host 
epithelial response to these differences could be clinically useful.
Previous studies have demonstrated promise for the diagnosis of BV using VOC  technology35,36. However, 
much of the previous VOC detection and analysis work deployed instruments which had several limitations for 
the clinical setting including the need for excessive training, substantial costs, significant data analysis, and con-
cerns with reproducibility of results, consequently these instruments were not amenable to become a rapid point 
of care test at that  time37. In our study we aimed to build on this work and assess whether novel VOC technology 
could detect BV and thus reflect vaginal flora. We aimed to identify if specific patterns of VOCs from vaginal 
swabs taken in pregnancy, were associated with preterm delivery in a population of pregnant women attending 
a preterm prevention clinic due to pre-existing risk factors for preterm birth using VOC detection and analysis 
technology involving machine learning, which with development has the potential to be translated into clinical 
practice and overcome the previously discussed concerns.
Approvals. The study was approved by the NHS Research Ethics Committee West Midlands Birmingham 
South on  14th January 2014 and sponsored by the University of Warwick. Approval from University Hospitals 
Coventry & Warwickshire Research & Development was acquired on  17th January 2014. All participants gave 
written informed consent. The study was funded by the Biomedical Research Unit in Reproductive Health, Uni-
versity of Warwick. Research was carried out according to The Code of Ethics of the World Medical Association 
(Declaration of Helsinki).
participants. The population was a prospective observational cohort of repeated sampling of 216 patients 
between weeks 10–29 of pregnancy (total 493 sets of swabs were taken, with at least 2 swabs per patient), from 
women attending the high-risk preterm prevention clinic at a tertiary level teaching hospital from January 
2017-August 2018. Women were excluded from analysis relating to preterm delivery if they required iatrogenic 
preterm delivery (n = 11) or delivery data were not available (n = 9). This left a remaining cohort of 196 women 
with spontaneous onset of labour at a known gestation. Demographic data including age at booking pregnancy, 
BMI, ethnicity, smoking status and indication for attendance to the preterm prevention clinic were collected 
about each woman (Table 1). An individualised management plan was made for each patient at their first visit, 
this was subject to modification dependent upon transvaginal ultrasound cervical length measurements. Some 
patients required cervical cerclage (history or ultrasound indicated) and other patients used vaginal progester-
one pessaries. Pregnancy outcome was obtained from clinical notes (Table 1). If patients were detected to have 
bacterial vaginosis using standard care, this was treated with a five day course of 2% clindamycin cream.
Results
chemical analyser. Figure 1 shows a typical output from the GC-IMS instrument for a preterm labour 
swab. The x-axis shows the drift time within the IMS and the y-axis the retention time of the GC (the time taken 
for the molecule to elude from the column). In Fig. 1, the background is dark blue, with the remaining colours 
being chemicals detected by the IMS. It also shows intensity with the red being the most abundant ions. The 
majority of the chemicals are seen as ‘circles’ on the output. The long red line in the y-axes is the systems response 
when there are no chemicals present. As can be seen, there is significant chemical information within the sample.
Sample group. Between January 2017 and August 2018, 493 vaginal swabs were taken from 216 women in 
pregnancy during their attendance to a preterm prevention clinic and birth outcome data collected. All women 
were asymptomatic for preterm birth. Their demographics are illustrated in Table 1.
Tests of normality were performed on the data, if data was identified to be parametric, students t t-tests was 
used and mean reported, if data was non-parametric Mann–Whitney U test were used for statistical analysis 
and median reported. For categorical variables chi square test was used.
As can be seen from Table 1 the baseline demographics were comparable between the two groups (with BV 
positive/BV negative or delivered term/delivered preterm) with the exception of maternal age in those women 
who delivered term compared to preterm. Those who delivered preterm were statistically significantly younger 
than those women who delivered at term. The indications for attendance to the clinic differed between the two 
groups. The number of women with a BV positive vaginal swab during pregnancy in our cohort was 26 (12.0%). 
The number of women who delivered preterm in our cohort was 39, corresponding to 19.9% of this high-risk 
population. 9.2% of deliveries were before 32 weeks gestation. Of the 23 women who had a positive test for BV in 
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Characteristic BV positive (n = 26) BV negative (n = 190) P value Term (≥ 37 + 0 weeks) (n = 157) Preterm (≤ 36 + 6 weeks) (n = 39) P value
Age
Mean (SD)- yrs 31.0 + /− 4.8 31.2 + /− 4.9 0.8666 31.6 ± 5.0 29.8 ± 4.4 0.0267*
Distribution-no. (%)
 < 35 yrs 17 (65.4) 142 (74.7) 111 (70.7) 34 (87.2)
 ≥ 35 yrs 9 (34.6) 48 (25.3) 46 (29.3) 5 (12.8)
BMI at bookinga
Median (IQR)-kg/m2 25.0 (22.5–33.0) 25.3 (22.2–29.4) 0.5074 25.3 (22.4–29.3) 25.3 (21.8–31.2) 0.8101
Distribution-no. (%)
  < 30 kg/m2 18 (69.2) 142 (77.6) 119 (75.8) 29 (74.4)
   ≥ 30 kg/m2 8 (30.7) 41 (22.4) 34 (21.7) 10 (25.6)
Ethnicityb–no. (%)
White 21 (80.8) 145 (76.3) 0.4597 124 (79.0) 33 (84.6) 0.0608
Black 4 (15.4) 20 (10.5) 19 (12.1) 0 (0)
Asian 1 (3.8) 15 (7.9) 12 (7.6) 4 (10.3)
Other 0 10 (5.3) 2 (1.3) 2 (5.1)
Smoking in pregnancy-no. (%)
Yes 4 (15.4) 21 (11.1) 0.8029 18 (11.5) 8 (20.5) 0.2015
No 20 (76.9) 152 (80.0) 127 (80.9) 30 (76.9)
Not known 2 (7.7) 17 (8.9) 12 (7.6) 1 (2.6)
Indication for attending clinic-no. 
(%)
Previous preterm ≥ 24 wk to < 34 wk 50 (31.9) 30 (76.9)  < 0.0001*
Previous midtrimester loss < 24 wk 38 (24.2) 4 (10.3)
History of cervical surgery 69 (43.9) 5 (12.8)
Gestation at delivery
Midtrimester miscarriage 1 1 – 2
Extreme preterm (< 28 weeks) 2 4 – 6
Very preterm (28–31 + 6 weeks) 3 8 – 10
Late preterm (32–36 + 6 weeks) 7 12 – 21
Term (≥ 37 weeks) 9 149 157 –
Not known 3 6 – –
Iatrogenic preterm delivery 1 10 – –
Figure 1.  Typical GC-IMS output to a vaginal swab. The x-axis refers to IMS drift time and the y-axis the 
retention time of chemicals eluding from the GC column.
Table 1.  Baseline characteristics. This includes 216 patients attending the preterm prevention clinic who had 
bacterial vaginosis diagnosed in pregnancy versus those who did not, and the 196 patients including who 
delivered preterm versus term (excluding those who had iatrogenic preterm delivery or if delivery information 
was not available). Pregnancy outcomes of patients recruited to the study from the preterm prevention clinic 
are illustrated. a BMI of 7 women in BV negative group not known and BMI of 4 women in term group not 
known. b Patient reported.
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pregnancy (and delivery data known), 13 went into spontaneous preterm labour (one was delivered preterm for 
iatrogenic reasons), corresponding to 59.1% (13/22). Of the women who had negative test for BV in pregnancy 
14.4% (25/174) delivered preterm.
Statistical results. The data from the VOC detection instruments was analysed as described in the meth-
ods section and the statistical output is shown in Table 2. This table also illustrates the gestation the swabs were 
taken in pregnancy and the number of days between when the swabs were taken and delivery. The ROC curves 
are illustrated in Fig. 2.
From Table 2, the mean gestation the first swab was taken in pregnancy did not differ between those who 
delivered at term and those who delivered preterm. The swab taken closest to delivery was taken nearer to delivery 
in the patients who delivered preterm. As expected, there was a shorter number of weeks from when the first 
swabs and swabs taken closest to delivery were taken in those who delivered preterm to those who delivered 
term. Table 2 also summarises the predictive statistics calculated using the methods described.
Discussion
This is the first study examining volatile organic compounds from vaginal swabs for the prediction of BV and 
preterm birth. As expected, VOC analysis did detect BV as this condition is known to be associated with specific 
odour. This finding could have some clinical utility in a rapid bedside diagnostic test for BV and this concept is 
currently being developed by  others38.
Our results showing that VOCs on vaginal swabs, taken in asymptomatic women attending a preterm preven-
tion clinic, could provide some useful information in predicting preterm labour. As preterm labour is a multi-
factorial condition the VOC test will only ever be able to predict some preterm births, and this is reflected in our 
specificity reported (0.65). Others, for example those caused by poor placental function or uterine anomalies are 
Table 2.  Statistical outputs for VOC analysis for the prediction of BV and preterm delivery from vaginal swabs 
taken in pregnancy. This table illustrates the gestation when the first swab was taken per patient in pregnancy 
and when the swab was taken closest to delivery per patient.
Classifier Random forest Gaussian process
Statistical output (95%CI) for prediction of bacterial vaginosis
AUC 0.92 (0.84–1) 0.94 (0.87–1)
Sensitivity 0.83 (0.65–0.94) 0.87 (0.69–0.96)
Specificity 0.97 (0.83–1) 0.93 (0.78–0.99)
Positive predictive value 0.96 0.93
Negative predictive value 0.85 0.88
p value  (between groups)  < 0.001  < 0.001
Delivered preterm Delivered term p value
First swab taken in pregnancy
Gestation when swab taken (weeks), Median (IQR) 17 + 4 (15 + 5 – 21 + 3) 16 + 6 (15 + 5 – 20 + 1) 0.3849
Number of weeks between swab taken and delivery, Median (IQR) 14 + 4 (10 + 1 – 17 + 1) 22 + 2 (19 + 1 – 24 + 0)  < 0.0001
Classifier Random forest Gaussian process
Statistical output (95%CI) for prediction of preterm delivery before 37 weeks
AUC 0.79 (0.72–0.85) 0.73 (0.66–0.80)
Sensitivity 0.66 (0.56–0.75) 0.67 (0.57–0.76)
Specificity 0.89 (0.82–0.95) 0.76 (0.66–0.84)
Positive predictive value 0.86 0.73
Negative predictive value 0.72 0.70
p value  (between groups)  < 0.001  < 0.001
Delivered preterm Delivered term p value
Swab taken closest to delivery
Gestation when swab taken (weeks), Median (IQR) 25 + 2 (22 + 6 – 27 + 1) 22 + 3 (18 + 5 – 25 + 5) 0.0019
Number of weeks between swab taken and delivery, Median (IQR) 7 + 2 (3 + 5 – 11 + 1) 17 + 1 (13 + 0 – 21 + 0)  < 0.0001
Classifier Random forest Gaussian process
Statistical output (95%CI) for prediction of preterm delivery before 37 weeks
AUC 0.84 (0.79–0.90) 0.77 (0.70–0.83)
Sensitivity 0.73 (0.64–0.81) 0.68 (0.58–0.76)
Specificity 0.9 (0.82–0.95) 0.76 (0.67–0.84)
Positive predictive value 0.88 0.74
Negative predictive value 0.77 0.70
p value  (between groups)  < 0.001  < 0.001
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Figure 2.  Receiver operator characteristic curves for VOC analysis of vaginal swabs for prediction of BV (a) 
and prediction of preterm labour (b, c) before 37 + 0 gestation from asymptomatic patients at an increased risk of 
spontaneous preterm birth for preterm delivery. (b) first swab taken in pregnancy (c) swab taken closest to delivery. 
(a) illustrates that VOC analysis is an excellent test for the diagnosis of BV with an AUC of 0.94. (b) demonstrates 
that taking a swab in the midtrimester and analysis of VOCs is a test which is fair for the subsequent prediction of 
preterm labour with an AUC of 0.79. (c) shows that VOC analysis of a swab taken later in pregnancy (late second 
or early third trimester) is a good test for the prediction of preterm birth with an AUC of 0.84.
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unlikely to be predicted using this test. The AUCs are good for the clinical context in prediction of spontane-
ous preterm birth in high risk asymptomatic women with the first swabs taken in the second trimester (AUC 
of 0.79), which improved in the last swabs taken closest to delivery (AUC 0.84). Of importance is that VOCs 
had a positive predictive value of up to 86% even when sampled 10–24 weeks before the event. This raises the 
possibility of using VOCs to develop a personalised approach to preterm labour prevention as there is plenty 
of time between the test and delivery to introduce preventative measures in susceptible individuals. Again, as 
expected, the nearer to delivery that the swab was taken the better the predictive performance and indeed the 
second swab taken 3–21 weeks before delivery had negative predictive value of up to 88% which could be useful 
clinically for planning location of delivery.
In our population, the indication for attendance to the preterm prevention clinic varied between those who 
delivered preterm or delivered at term. As expected, there was a higher proportion of those with a high-risk risk 
factor (previous second trimester loss) who went on to deliver preterm and higher proportion of those with an 
intermediate-risk risk factor (previous cervical surgery) who went on to deliver at  term39. Nearly two thirds of 
women who had a positive swab for BV, despite treatment went on to deliver preterm, supporting the previous 
studies that BV is associated with an increased risk of preterm birth but treatment for BV in pregnancy does 
not reduce the risk of preterm  delivery12,13. Future risk stratification using VOCs could include these variables 
as has been done successfully by  others40.
More recently cervical length measurement, quantitative fetal fibronectin and clinical factors have been 
combined and developed into a predictive model for preterm birth in asymptomatic women. This work has 
demonstrated that spontaneous preterm both can be accurately predicted with AUC values ranging from 0.75 
to 0.9040. VOCs have potential benefits, in addition to the existing published model for several reasons. Firstly 
because of the physiological difference between the tests. Quantitative fetal fibronectin is thought to detect 
inflammation of fetal membranes and together with the cervical length and clinical risk factors in the QUiPP 
App perhaps suggest cerclage or pessary to preterm  prevention40. In contrast the VOCs test is thought to detect 
a combination of the vaginal microbiome and the maternal response hence suggesting treatment to restore the 
vaginal  flora41 and reduce the maternal response to this flora perhaps with  progesterone42–44. Secondly, quantita-
tive fetal fibronectin is limited by the gestation at which it can be measured, after 22 weeks, this is not a limitation 
that applied to VOCs. Thirdly VOC analysis is likely to be a cheaper test requiring the purchase of a machine 
then using usual hospital swabs in the sensor rather than having to buy cassettes containing chemical assays per 
swab. We suggest that the addition VOC analysis to existing models could lead to the development of a test that 
is the basis of a personalised approach to preterm labour prevention. Much more work is needed to determine 
the use of VOCs in this field. We plan to compare our VOC analysis to the vaginal microbiome and determine 
if specific VOCs correlate with bacterial communities.
At this point in time, we do not have the specific biomarkers that resulted in these differences. Furthermore, 
we do not have any data about how individual patients vaginal VOCs change throughout gestation. In future 
studies we are planning to collect and analyse swabs throughout pregnancy and closer to delivery and undertake 
a deeper VOC analyses to understand how these specific VOCs change. Recent work on the vaginal microbi-
ome after 20 weeks gestation has demonstrated the microbiome diversity in both women who deliver preterm 
and term converges and remains stable for the remaining weeks of  pregnancy45, supporting the chances that 
the VOCs detected on our swabs could be similar from the midtrimester onwards. However, this is making the 
presumption that the host isn’t changing and influencing the VOCs produced. Steroid hormones are known to 
change throughout pregnancy, they could influence VOCs, which reflect interactions between the microbiome 
and the host.
In conclusion, this novel work has demonstrated that VOC analysis has the potential to be used as a predic-
tive tool to support the prediction of preterm birth and aid personalised prevention strategies. In the future this 
could be considered as an additional component to be utilised in models to help solve the multifactorial complex 
problem of accurate prediction and prevention of preterm delivery.
Methods
test methods. A speculum examination was performed and a vaginal swab taken for microbiology culture 
and sensitivity testing and for examination under the microscope using the Hay/Ison criteria. This was placed 
into a nonnutritive transport medium as per routine care. Concurrently, two cotton swabs were used to obtain 
index test vaginal samples for VOC analysis. The index test swabs were then placed in a universal containers 
and snap frozen in liquid nitrogen and stored at − 80 °C. Specimens were obtained by gently rotating the swabs 
across the mucosa of the vagina. Samples were taken in a consecutive series from all women who consented in 
the clinic, some women consented to samples being taken during every attendance to the clinic.
Swabs were analysed to first to assess whether VOCs could detect BV. Subsequently, the first swab, taken at 
the earliest gestation per patient was analysed using VOC detection technology to identify if specific VOC pat-
terns could be detected in those who went on to deliver preterm (before 37 + 0 weeks gestation). Then the swab 
taken closest to delivery per patient was analysed using VOC detection technology to identify if specific VOC 
patterns predicted preterm birth.
chemical analyzer. For chemical vapour analysis, index swabs were shipped to the BioMedical Sensors 
Laboratory, School of Engineering, University of Warwick. The odours/VOCs emanating from the samples were 
analysised using G.A.S. GC-IMS instrument (Dortmund, Germany), which is based on Gas Chromatograph – 
Ion Mobility Spectrometery principles (GC-IMS). This is a highly sensitive odour detection technology that has 
been previously used by our group in clinical studies analysing a range of biological  samples46,47. In brief, the 
GC front end is used to pre-separate molecules based on their interaction with a stationary phase coating on a 
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long column, eluding from the column at different times. These molecules are then ionized (in our case with a 
tritium sounce) and enter a drift tube IMS. Here, the ions are pushed through a tube by applying an electric field 
and detected as they exit the tube. Against the flow of sample ions, a buffer gas is pushed through the tube in 
the opposite direction to the ions. In general, large sample molecules were struck many times and slowed down, 
whilst smaller sample molecules were struck less and kept their momentum. Therefore, drift time is a function 
of the interaction between the electric field the buffer gas and the ions. This instrument was chosen over more 
traditional GCMS, as the basic sensitivity of the instrument is much higher, it can use nitrogen as the carrier 
gas (so no expensive gas such as helium), has a lower unit cost than GCMS and has a smaller form factor, thus 
has the potential to be used on a ward setting. However, a limitation of this setup was that we were unable to 
identify specific VOC biomarkers. Thus, the output of the instrument was analysed using a pattern recognition 
technique.
chemical testing and analysis. Samples were shipped from University Hospitals Coventry and War-
wickshire to Warwick University on dry-ice and briefly stored at − 20 °C before testing. Sample preparation 
comprised of thawing the swab at 4 °C and transferring it to a 20 ml gas vial, which is subsequently sealed with 
a crimp top lid fitted with a PTFE septum. Prior to measurement samples were heated to 40 °C for 10 min. The 
sample line for the GC-IMS was inserted into the septa of the vial using a needle and 2 ml of sample was pulled 
into the analytical platform. The machine settings were as follows: E1: 150 ml/min (for the drift tube IMS), E2: 
20 ml/min (for the GC column) and the pump at 25% total power. The total run time was 10 min. The tempera-
tures were set to: T1: 45 °C, T2: 80 °C, and T3: 70 °C.
Statistical analysis. For data analysis, the data was first extracted from the native file format to a text 
file using the L.A.V. Software (G.A.S. Dortmund, Germany). Then dimentional reduction steps were used to 
decrease the number of datapoints and remove the backgound. This is undertaken as the data has high dimen-
sionality (typically 11 million data points per sample), but low information content, with the majority of the 
data located in the centre of the output (shown in Fig. 1). To reduce the dimensionality of the data, a crop is first 
applied that reduces the output to the data to this central section. The values of this crop are selected manually by 
inspection of a large number of samples to ensure that all the chemical information is contained within it. Once 
selected, the same crop values are applied to all the samples automatically. Then a threshold is used to remove the 
background, which contains no useful information. Again, this process is undertaken by manual inspection and 
then the same value applied to all of the samples automatically. These processes reduce the number of non-zero 
data points by a factor of × 100, which in turn reduces the computation overhead of analyzing the data. Once 
completed, the data was analysed using a tenfold cross validation. Within each fold, the data was divided into 
a 90% training set and a 10% test set. Features with discriminary power were identified from the training set 
using a rank-sum test and 100 features with the lowest p value were taken forward for classification. Then, two 
different classifiers, specifically Random Forest and Gaussian process, were applied. These have previously been 
found to be good classifiers for GC-IMS  data46,47. Once the training models have been created, they were applied 
to the same features in the test set. This process is repeated ten times until all the data has a test result. Utilising 
this method, we needed to have the same number of index test positive and negative samples, negative samples 
were chosen at random. This process provided test probabilities for each sample and from this, statistical values, 
including sensitivity and specificity were calculated.
ethics approval. The study protocol was approved by the NHS Research Ethics Committee West Midlands 
Birmingham South on 14th January 2014 (13/WM/0486).
Data availability
The raw demographic data is available in the supplementary material section. Raw data are available to readers 
but due to the large file sizes these are held on Zenodo via the following link https ://zenod o.org/recor d/39021 
15#.XvCJ5 C2ZNb V
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